Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
ANN ARBOR, Mich., Feb. 20, 2018 -- Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (TSX-V:ZOM) (“Zomedica” or “Company”), a veterinary diagnostic and pharmaceutical company, today announced its participation in the Bank of America Merrill Lynch Animal Health Summit on Monday, February 26, 2018, in New York, NY.
Chief Financial Officer Shameze Rampertab, CPA, CA, is part of a panel discussion on “Innovation in Companion Animal Therapeutics” at 8:40 a.m. E.T. and will be available to participate in one-on-one meetings to discuss Zomedica’s pipeline development and key milestones with investors registered to attend the conference.
About Zomedica
Based in Ann Arbor, Michigan, Zomedica (NYSE American:ZOM) (TSX-V:ZOM) is a veterinary diagnostic and pharmaceutical company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. Zomedica’s product portfolio will include novel diagnostics and innovative therapeutics that emphasize patient health and practice health. With a team that includes clinical veterinary professionals, it is Zomedica’s mission to give veterinarians the opportunity to lower costs, increase productivity, and grow revenue while better serving the animals in their care. For more information, visit www.ZOMEDICA.com.
Follow Zomedica
- Email Alerts: http://investors.zomedica.com/
- LinkedIn: https://www.linkedin.com/company/zomedica
- Facebook: https://www.facebook.com/zomedica/
- Twitter: https://twitter.com/zomedica
Reader Advisory
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the release.
Investor Relations Contact
Shameze Rampertab, CPA, CA
[email protected]
+1 647.283.3630
PCG Advisory Group
Kirin Smith, COO
[email protected]
+1 646.863.6519
www.pcgadvisory.com
Media Contact
Andrea Eberle
[email protected]
+1 734.369.2555
